Literature DB >> 9721172

Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child.

M Srivastava1, A Perez-Atayde, M M Jonas.   

Abstract

Acute vanishing bile duct syndrome is a rare but established cause of progressive cholestasis in adults, is most often drug or toxin related, and is of unknown pathogenesis. It has not been reported previously in children. Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations. A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use. Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation. This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9721172     DOI: 10.1016/s0016-5085(98)70154-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  13 in total

1.  Efficacy of early immunosuppressive therapy in a child with carbamazepine-associated vanishing bile duct and Stevens-Johnson syndromes.

Authors:  Monica Garcia; Maroun J Mhanna; Moon-Ja Chung-Park; Pamela H Davis; Maya D Srivastava
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

2.  Colonic involvement in Stevens-Johnson syndrome.

Authors:  N Powell; J M Munro; D Rowbotham
Journal:  Postgrad Med J       Date:  2006-06       Impact factor: 2.401

3.  Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus.

Authors:  Gokhan Okan; Serpil Yaylaci; Onder Peker; Sabahattin Kaymakoglu; Murat Saruc
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

Review 4.  Drug-induced cholestasis.

Authors:  Manmeet S Padda; Mayra Sanchez; Abbasi J Akhtar; James L Boyer
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

5.  Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and Treatment With a Biologic: A Case Report.

Authors:  Ian Chong; Alice Chao
Journal:  Perm J       Date:  2017

6.  Development of an experimental model of cholestasis induced by hypoxic/ischemic damage to the bile duct and liver tissues in infantile rats.

Authors:  Fumiaki Toki; Atsushi Takahashi; Makoto Suzuki; Sayaka Ootake; Junko Hirato; Hiroyuki Kuwano
Journal:  J Gastroenterol       Date:  2011-02-25       Impact factor: 7.527

Review 7.  Infliximab/Plasmapheresis in vanishing bile duct syndrome secondary to toxic epidermal necrolysis.

Authors:  Jason C White; Stephanie Appleman
Journal:  Pediatrics       Date:  2014-09-22       Impact factor: 7.124

Review 8.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

9.  Ibuprofen associated acute vanishing bile duct syndrome and toxic epidermal necrolysis in an infant.

Authors:  Hye-young Kim; Hea Kyoung Yang; Seong Heon Kim; Jae Hong Park
Journal:  Yonsei Med J       Date:  2014-04-01       Impact factor: 2.759

10.  Urosodeoxycholic Acid Therapy in a Child with Trimethoprim-Sulfamethoxazole-induced Vanishing Bile Duct Syndrome.

Authors:  Hyun Jeong Cho; Hye Jeong Jwa; Kyu Seon Kim; Dae Yong Gang; Jae Young Kim
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2013-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.